Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345117 | 1.00 | LMNA (0.62) | LMNAHTTPKMMAPK10GABRA5 | |
| SCHEMBL6206854 | 0.87 | LMNA (0.54) | LMNAHTTPKMMAPK10MEN1 | |
| SCHEMBL4915141 | 0.85 | LMNA (0.70) | LMNAHTTMEN1CYP1A2KMT2A | |
| SCHEMBL6980977 | 0.83 | PKM (0.79) | PKMMAPK10MEN1CYP1A2KMT2A | |
| SCHEMBL2762074 | 0.82 | LMNA (0.81) | LMNAHTTMEN1CYP1A2KMT2A | |
| SCHEMBL23119670 | 0.81 | LMNA (0.57) | LMNAHTTGABRA5GABRA1MEN1 | |
| SCHEMBL5242200 | 0.80 | GRIN1 (0.48) | PKMMAPK10GABRA5GABRA1MEN1 | |
| SCHEMBL30336835 | 0.78 | ROCK2 (0.46) | LMNAHTTCYP1A2KDM4EALDH1A1 | |
| SCHEMBL23997431 | 0.78 | ROCK2 (0.46) | LMNAHTTCYP1A2KDM4EALDH1A1 | |
| SCHEMBL4917013 | 0.77 | LMNA (1.00) | LMNAHTTMAPK10GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2021226003-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20080058376-A1 | PIPERIDINES | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| EP-0005610-B1 | 1-(HETEROCYCLYLALKYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONES, THEIR PREPARATION, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS BETA-ADRENERGIC RECEPTOR BLOCKERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-12-15 | — | — | EP | disclosed |
| US-4181802-A | ADRENERGIC BLOCKING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-01-01 | — | — | US | disclosed |
| EP-0005610-A2 | 1-(Heterocyclylalkyl)-1,3-dihydro-2H-benzimidazol-2-ones, their preparation, their pharmaceutical compositions and their use as beta-adrenergic receptor blockers | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | LMNA 4017/4885HTT 4501/4885PKM 4163/4885 |
| US-20080058376-A1 | PIPERIDINES | TRPV3, SCN3A, TRPV1 | LMNA 2484/4885HTT 1281/4885PKM 1659/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | LMNA 3635/4885HTT 1142/4885PKM 3703/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | LMNA 3635/4885HTT 1142/4885PKM 3703/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | LMNA 4017/4885HTT 4501/4885PKM 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.